U.S. Stock Movement | Hims & Hers Health rises over 7% as it will launch exclusive oral testosterone therapy

On Wednesday, Hims & Hers Health's stock price rose, and as of the time of writing, the stock was up over 7%, trading at $51.39. In terms of news, the company announced that in 2026, it will exclusively launch an oral testosterone medication, KYZATREX®, on its platform in collaboration with Marius Pharmaceuticals, a leader in testosterone therapy innovation. This medication has been approved by the U.S. Food and Drug Administration and does not require injections, making it more convenient to use. According to clinical data, KYZATREX® can help up to 96% of men restore normal testosterone levels while doubling "free testosterone." Free testosterone is believed to be closely related to energy, drive, and physical performance, and the medication maintains a low adverse reaction rate while enhancing efficacy